ArticleJournal of thoracic disease2026
Maximum standardized uptake value significance in clinical stage IB-IIIB non-small cell lung cancer.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, the number of treatment options for locally advanced non-small cell lung cancer (NSCLC) has increased, including neoadjuvant therapy. Accurate preoperative evaluation of malignancy can assist in planning of therapeutic strategies for NSCLC. We evaluated whether the maximum standardized uptake value (SUVmax) could serve as a predictive prognostic factor for locally advanced clinical stage IB to IIIB NSCLC. Methods: We enrolled 396 patients with clinical stage IB-IIIB NSCLC who underwent lobectomy at the Kanagawa Cancer Center between January 2012 and December 2021. All patients underwent preoperative positron-emission tomography/computed tomography at our institution. The SUVmax cutoff value was determined using a receiver operating characteristic curve. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using Kaplan-Meier curves and were compared using log-rank tests. Factors associated with RFS and OS were determined using a Cox proportional hazards model. Results: Multivariate analysis demonstrated that the SUVmax of the primary tumor was independently associated with RFS and OS in clinical stage IB to IIIB NSCLC patients. SUVmax could stratify both the RFS and OS of patients, particularly from clinical stage IB to IIB. Furthermore, the rates of pathological upstaging and distant recurrence were higher in patients with resected clinical stage IB to IIIB NSCLC with a high SUVmax (>6.0) than in those with a low SUVmax (≤6.0). Conclusions: The SUVmax of the primary tumor is an important preoperative predictor of prognosis in clinical stage IB to IIIB NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.